Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck, Serum Institute Face-off Looms With HPV Vaccination Support In India’s Interim Budget

Serum To Hike Capacity, Will Merck Drop Prices?

Executive Summary

A mention in India’s interim budget of support for HPV vaccination is heartening for Serum Institute and Merck as it is seen as a precursor to the vaccine’s inclusion in the country’s Universal Immunization Program, one of the largest public health programs globally. As Serum plans to expand capacity, will Merck drop Gardasil prices for a piece of the UIP pie?

You may also be interested in...

Could US Drug Shortages Worsen After Aurobindo’s Eugia Plant Setbacks?

FDA’s observations at Aurobindo subsidiary Eugia's plant in India and a new one in New Jersey could lead to more drug shortages in the US, particularly injectables, though the company aims to streamline production by end-March. Meanwhile, it will capitalize on the “sizable opportunity” from the EU's list of critical medicines while launching a Herceptin biosimilar in India

Merck & Co. Heads Into A Year Of Portfolio Expansion

The company expects new products like the pneumococcal vaccine V116, the PAH treatment sotatercept and the ADC patritumab deruxtecan will begin contributing to revenue growth in the near term.

GSK Can Finally Claim A Turnaround Thanks To Arexvy’s Blockbuster Launch

GSK’s RSV vaccine Arexvy is a clear early winner against Pfizer’s rival, prompting analysts to finally turn optimistic about the company’s long-term prospects.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts